Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 18;6(2):155-9.
doi: 10.3980/j.issn.2222-3959.2013.02.09. Print 2013.

Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany

Ulrich Thelen  1 , Dietmar Schnober, Sonja Schölzel, Michael S Kristoffersen, Lindsay A Nelson, Jeanette A Stewart, William C Stewart
Affiliations

Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany

Ulrich Thelen et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate 5-year effectiveness and cost between latanoprost or timolol monotherapy in a pilot trial.

Methods: A retrospective, multi-center trial performed at 6 sites in Germany of patients who had a diagnosis of primary open-angle or pigmentary glaucoma, in at least one eye, initiated on monotherapy with latanoprost or timolol maleate. Qualified consecutive charts were reviewed in which 5-year efficacy, safety and cost data was abstracted.

Results: Seventy-seoen latanoprost and 49 timolol patients were included, at the final visit no difference existed between the two groups in disc parameters including: rim area, rim area/disc area ratio, cup volume or vertical cup/disc ratio (P>0.05). There was no difference in intraocular pressure (IOP) between the initial latanoprost (17.4±2.6) and timolol (16.3±2.8mmHg) groups. There was less change in medicines over the follow-up period (0.1 vs 0.8) and fewer medications at the final visit (1.2 vs 1.8) with latanoprost compared to timolol. No patient treated with latanoprost discontinued therapy during follow-up, while 12% discontinued timolol mostly due to inadequate IOP control. Cost/year was less with initial timolol ($458±236) as compared to latanoprost ($552±202).

Conclusion: Patients begun on latanoprost or timolol and followed over 5 years may have similar clinical outcomes. However, timolol patients may require more medicines and medicine changes to control IOP for long-term, but at a lower cost.

Keywords: Germany; economic; efficacy; glaucoma; latanoprost; safety; timolol.

PubMed Disclaimer

References

    1. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology. 2006;103(11):1916–1924. - PubMed
    1. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115(7):1117–1122. - PubMed
    1. Van der Valk R, Webers C, Schouten J, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs-a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177–1185. - PubMed
    1. Van der Valk R, Webers C, Lumley T, Hendrikse F, Prins MH, Schouten JS. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009;62(12):1279–1283. - PubMed
    1. Day DG, Schacknow PN, Sharpe ED, Ellyn JC, Kulze JC, 3rd, Threlkeld AB, Jones ED, Brown RH, Jenkins JN, Stewart WC. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2004;20(5):383–392. - PubMed

LinkOut - more resources